On December 12, 2023 Immodulon, a late-stage clinical biotechnology company focused on developing a broad spectrum immunomodulator to improve the lives of patients suffering from difficult-to-treat cancers, reported the formation of a new Scientific Advisory Board comprising leading global experts in the field of clinical oncology (Press release, Immodulon Therapeutics, DEC 12, 2023, View Source [SID1234638494]). The new SAB will be chaired by Prof. Dr. med. Thomas Seufferlein, Director, Department of Gastroenterology, University of Ulm, Germany, and will complement the experience of Immodulon’s new management team to support the advancement of IMM-101 into a pivotal trial for pancreatic cancer as well as broader pipeline progress.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"I am excited about the opportunity to partner with such an esteemed group of scientific advisors who are committed to supporting the development of IMM-101 to treat immunologically cold tumors, including pancreatic cancer," said Josefine Roemmler-Zehrer, MD, Associate Professor, and Immodulon’s Chief Medical Officer. "I am confident that their guidance will be crucial to moving IMM-101 into a pivotal trial for pancreatic cancer, following the completion of a positive Phase 2 trial, and accelerating our efforts to bring its therapeutic potential closer to cancer patients in need."
"I am delighted to chair this board of global experts in pancreatic cancer. My fellow SAB members and I are looking forward to supporting the Immodulon team in their efforts to develop IMM-101 into an effective treatment for patients with metastatic pancreatic cancer," said Prof. Dr. Thomas Seufferlein, Chair of Immodulon’s Scientific Advisory Board.
The new SAB consists of the following members:
Prof. Dr. med. Thomas Seufferlein (Chairman), University of Ulm, Ulm, Germany
Dr. Jean-Pierre Bizzari, MD, Former EVP, Group Head ClinicalDevelopment Oncology at Celgene
Prof. David Chang, MBBS, MS, FRACS, FRCS, PhD, University of Glasgow, Glasgow, UK
Prof. Angus Dalgleish, MD, FRCP, FRACP, FRCPath, St. Georges University Hospital, London, UK
Dr. Andrew Gaya, BSc, MB SC, MRCP, FRCR, MD, Guy’s and St Thomas’ Hospital, London, UK
Prof. Jeeyun Lee, MD, Sungkyunkwan University, Samsung MC,Seoul, ROK
Prof. Andrew MacDonald, BSc, PhD, University of Manchester, Manchester, UK
Dr. Victoria Manax, MD, Managing Partner MRCD Consulting
Prof. Josep Tabernero, MD, PhD, Vall d’Hebron University, Barcelona, Spain
Prof. Dr. Margaret Tempero, MD, USCF, CA, United States
Prof. Dr. Eric Van Cutsem, MD, University of Leuven, Belgium